The estimated Net Worth of Jeffrey Yordon is at least $1.44 Milión dollars as of 3 August 2022. Mr. Yordon owns over 12,500 units of Athenex Inc stock worth over $49,921 and over the last 7 years he sold ATNX stock worth over $0. In addition, he makes $1,387,830 as Chief Operating Officer and President a Athenex Pharmaceutical Division at Athenex Inc.
Jeffrey has made over 5 trades of the Athenex Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 12,500 units of ATNX stock worth $2,500 on 3 August 2022.
The largest trade he's ever made was exercising 18,180 units of Athenex Inc stock on 10 September 2020 worth over $199,980. On average, Jeffrey trades about 4,598 units every 133 days since 2017. As of 3 August 2022 he still owns at least 249,606 units of Athenex Inc stock.
You can see the complete history of Mr. Yordon stock trades at the bottom of the page.
Jeffrey M. Yordon serves as Chief Operating Officer and President, Athenex Pharmaceutical Division of the Company. Mr. Yordon joined our company as President, Athenex Pharmaceutical Division in April 2016 and in February 2017 he was appointed as our Chief Operating Officer. Mr. Yordon has held multiple senior management positions in the pharmaceutical industry over the last 46 years. Mr. Yordon was the Founder, Chairman and Chief Executive Officer of Sagent Pharmaceuticals from 2007 until joining us in 2016. Prior to that Mr. Yordon was the COO of American Pharmaceutical Partners where he was a co-founder until the company was eventually sold to Fresenius. Mr. Yordon was the CEO of Faulding Pharmaceuticals, CEO and founder of YorPharm, COO of Gensia Pharmaceuticals and he was involved in the sale of each of these companies to Apotex, Teva and Hospira, respectively. Mr. Yordon was an Ernst & Young Entrepreneur of the Year in 2011, was inducted into the Chicago Entrepreneur Hall of Fame in 2014, won a prestigious Innovation Award from the City of Chicago, was appointed to the Chicago Innovation Council in 2014, was appointed by Governor Rauner to the Illinois Sports Facilities Authority in 2015, has been appointed to be the Chairman of the Board of the Northern Illinois University Foundation, is the Chair of the NIU Political Science Advisory Panel and is actively involved in the NIU Athletic program. Mr. Yordon received a B.A. in Political Science from Northern Illinois University.
As the Chief Operating Officer and President a Athenex Pharmaceutical Division of Athenex Inc, the total compensation of Jeffrey Yordon at Athenex Inc is $1,387,830. There are 2 executives at Athenex Inc getting paid more, with Johnson Lau having the highest compensation of $4,483,840.
Jeffrey Yordon is 71, he's been the Chief Operating Officer and President a Athenex Pharmaceutical Division of Athenex Inc since 2017. There are 3 older and 13 younger executives at Athenex Inc. The oldest executive at Athenex Inc is John Vierling, 74, who is the Independent Director.
Jeffrey's mailing address filed with the SEC is C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO, NY, 14203.
Over the last 7 years, insiders at Athenex Inc have traded over $33,215,399 worth of Athenex Inc stock and bought 5,920,005 units worth $73,651,360 . The most active insiders traders include Advisors Llcperceptive Life..., Song Yi Zhang a Song Yi Mandra Medical Ltd .... On average, Athenex Inc executives and independent directors trade stock every 12 days with the average trade being worth of $10,843. The most recent stock trade was executed by Joe Annoni on 22 February 2023, trading 625 units of ATNX stock currently worth $125.
athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. the company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. our business includes medical technology innovation centers and a unique manufacturing supply chain across both china and north america. through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.
Athenex Inc executives and other stock owners filed with the SEC include: